The physician will diagnose CIDP using EMG and nerve conduction velocity testing, spinal tap, MRI, and blood tests, as well as, in rare cases, a nerve biopsy. Treatment of CDIP includes ...

Chronic inflammatory demyelinating polyneuropathy (CIDP) results in disability through immune-mediated nerve injury, which can lead to irreversible deficits after the inflammatory component of ...

In recent years, CIDP has received increasing attention due to its high misdiagnosis rate, along with the publication of new ...

The report encompasses critical data on emerging therapies designed to ameliorate the lives of those living with CIDP, indicating a progressive shift towards novel treatment modalities.

Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is a progressive or relapsing neuropathy likely caused by an autoimmune attack on the peripheral nerves. A number of treatment ...

Takeda Canada Inc. (Takeda) is pleased to announce that Health Canada has expanded the marketing authorization for HyQvia® ...

In a statement, Argenx said that the subcutaneously administered drug is the first “meaningful” new treatment option for the approximately 24,000 people living with CIDP in the US in more than ...

Immunovant, Inc. had positive results for batoclimab in trials for Myasthenia Gravis & CIDP; Thyroid Eye Disease data expected in 2025. Click for my IMVT update.

Other CIDP scales also demonstrated meaningful improvements ... a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis, non-infectious uveitis ...

The phase IIb study is evaluating batoclimab in CIDP patients whose disease had worsened during standard-of-care treatment. CIDP is a rare autoimmune neurological disorder that causes progressive ...